Orchestra BioMed Holdings, Inc.

NasdaqGM:OBIO Stock Report

Market Cap: US$206.8m

Orchestra BioMed Holdings Management

Management criteria checks 2/4

Orchestra BioMed Holdings' CEO is David Hochman, appointed in May 2018, has a tenure of 6.5 years. total yearly compensation is $6.90M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 1.07% of the company’s shares, worth $2.22M. The average tenure of the management team and the board of directors is 2.2 years and 6 years respectively.

Key information

David Hochman

Chief executive officer

US$6.9m

Total compensation

CEO salary percentage8.6%
CEO tenure6.5yrs
CEO ownership1.1%
Management average tenure2.2yrs
Board average tenure6yrs

Recent management updates

Recent updates

Orchestra BioMed Holdings (NASDAQ:OBIO) Has Debt But No Earnings; Should You Worry?

Mar 01
Orchestra BioMed Holdings (NASDAQ:OBIO) Has Debt But No Earnings; Should You Worry?

CEO Compensation Analysis

How has David Hochman's remuneration changed compared to Orchestra BioMed Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$58m

Jun 30 2024n/an/a

-US$56m

Mar 31 2024n/an/a

-US$52m

Dec 31 2023US$7mUS$595k

-US$49m

Sep 30 2023n/an/a

-US$46m

Jun 30 2023n/an/a

-US$43m

Mar 31 2023n/an/a

-US$39m

Dec 31 2022US$3mUS$395k

-US$34m

Sep 30 2022n/an/a

-US$32m

Jun 30 2022n/an/a

-US$27m

Mar 31 2022n/an/a

-US$25m

Dec 31 2021US$710kUS$395k

-US$23m

Compensation vs Market: David's total compensation ($USD6.90M) is above average for companies of similar size in the US market ($USD1.47M).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Hochman (49 yo)

6.5yrs

Tenure

US$6,899,668

Compensation

Mr. David P. Hochman is Founder & Director at Orchestra BioMed Holdings Inc. (formerly known as Health Sciences Acquisitions Corporation 2) since May 2018 and serves as its Chief Executive Offer and Chairm...

Leadership Team

NamePositionTenureCompensationOwnership
David Hochman
Founder6.5yrsUS$6.90m1.07%
$ 2.2m
Darren Sherman
Founder6.5yrsUS$6.45m0.61%
$ 1.3m
Andrew Taylor
Chief Financial Officer1.4yrsUS$2.57mno data
William Little
Executive Vice President of Corporate Development & Strategy1.4yrsno data0.81%
$ 1.7m
Yuval Mika
GM & CTO of Bioelectronic Therapies6.5yrsno data0.13%
$ 269.7k
George Papandreou
GM & Senior VP of Focal Therapies3.3yrsno data0.053%
$ 108.8k
Hans-Peter Stoll
Chief Clinical Officer2.6yrsno datano data
Avraham Fischer
Senior Vice President of Medical Affairs & Innovation1.8yrsno datano data
Bob Laughner
Senior Vice President of Regulatory & Qualityless than a yearno datano data
Juan Lorenzo
Senior Vice President of Product Developmentless than a yearno datano data
Joshua Aiello
Corporate Controllerno datano datano data

2.2yrs

Average Tenure

53yo

Average Age

Experienced Management: OBIO's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Hochman
Founder6.5yrsUS$6.90m1.07%
$ 2.2m
Darren Sherman
Founder6.5yrsUS$6.45m0.61%
$ 1.3m
Eric Rose
Independent Director5.9yrsUS$138.07k0.0057%
$ 11.8k
Paul Teirstein
Member of Medical Advisors Boardno datano datano data
Vivek Reddy
Member of Medical Advisors Boardno datano datano data
Eric Fain
Independent Lead Director6yrsUS$243.42k0.094%
$ 194.9k
Robert Schwartz
Member of Medical Advisors Boardno datano datano data
Jason Aryeh
Independent Director6yrsUS$145.21k0.17%
$ 342.6k
Stefan Verheye
Member of Medical Advisors Boardno datano datano data
Roger de la Torre
Member of Medical Advisors Boardno datano datano data
Pieter Stella
Member of Medical Advisors Boardno datano datano data
Pamela Connealy
Independent Director4.8yrsUS$205.42k0.011%
$ 23.1k

6.0yrs

Average Tenure

59yo

Average Age

Experienced Board: OBIO's board of directors are considered experienced (6 years average tenure).